SyntheX

SyntheX

A biotechnology and pharmaceutical company headquartered in San Francisco, California that was founded in 2016 by Charly Chahwan and Maria Soloveychik developing treatments for cancer and other diseases.

SyntheX is a biotechnology and pharmaceutical company that was founded by Charly Chahwan and Maria Soloveychik in 2016, and is headquartered in San Francisco, California. SyntheX uses a proprietary drug design approach and in-vivo screening platform, ToRPPIDO, to identify compounds that disrupt protein-protein interactions (PPIs). Their lead stabilized peptide inhibitor drugs, STX101 and STX105, block PPIs within the BRCA2 pathway, mimicking a BRCA2 mutation.

The SyntheX drug development technology can be used for creating drug products for use in oncology, membrane proteins, orphan diseases, antibiotic development, neuroinflammation, and immunology.

Compound development

Synthex has 3 types of compounds in development: STX100's, STX200s, and STX300's. The STX100 includes compounds for HR-driven liver cancer, HR -driven pancreatic cancer, non-small cell lung cancer, and glioblastoma multiforme. The STX200 compounds are being made to treat KRAS-driven cancers, and the STX300 compounds are being made for an undislcosed target.

Funding

Convertible note

On March 10, 2016 SyntheX received a convertible note worth $250 thousand from SOSV and IndieBio.

Seed round

On April 20, 2017 SyntheX closed their seed funding round with $6.2 million in seed round funding from Morgan Noble, SOSV, Oriza Ventures, and 8VC.

Timeline

People

Name
Role
LinkedIn

Charly Chahwan

Founder

Maria Soloveychik

Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.